Big Pharma Sharma
Unvarnished takes on Big Pharma strategy, M&A patterns, and competitive positioning. What CEOs are actually signaling—before Wall Street sees it
| Platform |  | Pricing | Freemium | Publishes | Weekly |
|---|---|---|---|---|---|
| Issues | 123 | Founded | 3 years ago | Last Issue | 17 days ago |
| Active | |||||
Read this Newsletter
bigpharmasharma.comLatest Issues
Last Week Tonight in BioPharma: Week of July 20, 2026
Welcome back to Last Week Tonight in BioPharma (LWTB). What a week!
This week, GSK cashed its first lung cancer chip from the $10.6B Nuvalent buy with an FDA approval for JIDEYTRO, Eli Lilly posts more pivotal retatrutide data but people a...
Last Week Tonight in BioPharma: Week of July 13th, 2026
Welcome back to Last Week Tonight in BioPharma (LWTB)!
This week: Merck gets the first oral PCSK9 inhibitor approved, Kalshi opens prediction markets for clinical trial outcomes, and Eli Lilly enters the psychedelics space with its acquisi...
Will That Be Cash or Credit?
Pay attention to the way Big Biopharma pays for its acquisitions — it can tell you a lot
Hasn’t it felt like there’s been a lot of deals this year? We’re only through about half the year and it certainly feels like it. Back in April, the f...
Last Week Tonight in BioPharma: Week of July 7th, 2026
Welcome back to Last Week Tonight in BioPharma (LWTB)!
This week: AstraZeneca and Ionis see disappointing results in ATTR Cardiomyopathy, Vera sees accelerated approval of TRUTAKNA ahead of eGFR data in Q3, the FDA pauses CRLs but then res...
Last Week Tonight in BioPharma: Week of June 29th, 2026
Welcome back to Last Week Tonight in BioPharma (LWTB). Hope you had an enjoyable Fourth of July weekend. LWTB is here to catch you up on what you missed while you were away.
Roche’s divarasib became the latest RAS inhibitor to register im...
Audience Metrics
Subscribers, engagement, traffic and sponsorship for Big Pharma Sharma.
| Subscribers | Engagement | 72 | Monthly Web Visits | ||
|---|---|---|---|---|---|
| Accepts Sponsors | Estimated Cost per Ad | ||||
Explore More
Authors
The writers behind this newsletter.
Drug Strategist. Delivering insider analyses and insights on all things BioPharma.
Frequently Asked Questions
How can I access the email archive for Big Pharma Sharma?
You can find recent issues that have been published by Big Pharma Sharma on Reletter by scrolling up to where it says Latest Issues. Tap on the link for any of the most recent emails or hit More Issues to see older ones.
How many subscribers does Big Pharma Sharma have?
To see how many people subscribe to Big Pharma Sharma, simply upgrade your Reletter account. We provide readership numbers and lots of other stats for this newsletter so you can decide if it's worth reaching out to.
How can I advertise in Big Pharma Sharma?
Newsletter advertising can be extremely effective when it's done right. Before you pitch Big Pharma Sharma as a potential sponsor or partner, make sure that you've done your research and checked its newsletter stats with Reletter.
Then, personalize one of our winning pitching templates and send it to the right person using the contact info provided.
How much does it cost to sponsor a publication like Big Pharma Sharma?
Newsletter ad rates (or CPM) vary depending on many factors, including industry, number of subscribers, open rate, ad placement and more.
To find out how much an ad will cost, contact Big Pharma Sharma using the contact information provided and ask for a copy of their media kit.
How can I find newsletters related to Big Pharma Sharma?
Scroll up to where it says Related Newsletters to see other publications like Big Pharma Sharma. You can also search our email newsletter directory to discover other newsletters that cover the topics you're interested in.
How do I contact Big Pharma Sharma?
Reletter provides this newsletter's website URL above, where you will often find their contact information. We also provide links to associated social media accounts and pitching templates so you can reach out fast.